Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan could spot cancer spread sooner, boosting survival

NCT ID NCT06877949

Knowledge-focused Sponsor: Odense University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two types of scans—FDG-PET/CT and standard CT—to see which one better tracks breast cancer that has spread. Researchers want to know if the newer scan can find cancer growth earlier, helping doctors start new treatments sooner and potentially extend patients' lives. About 420 adults with newly diagnosed metastatic breast cancer will be randomly assigned to one scan type and followed over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 420 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Women and men aged ≥18 years 2. Diagnosis of distant relapsed MBC (biopsy-verified) or de novo breast cancer. In patients with distant relapsed MBC, biopsy verification from a distant metastasis is required. In patients with de novo MBC, biopsy verification of primary tumor and diagnostic imaging with distant metastasis with a typical pattern of MBC is required. 3. Considered eligible for first-line systemic treatment 4. Considered eligible for continuous treatment monitoring by scans. 5. Signed informed consent 6. Participants must have the ability to read and understand the following languages based on their country of participation: in Denmark, patients must be able to read and understand Danish; in Italy, they must be able to read and understand Italian or English; and in Germany, they must be able to read and understand German or English. In case of patients for whom it is necessary to start first-line systemic treatment while still waiting for the evaluation of the biopsy, it is allowed to include the patients, as long as the other criteria are fulfilled and the biopsy is made or planned. In case verification by biopsy fails, the patients will leave the trial (cf. 4c). We expect that up to 3% of the patients included will start first-line systemic treatment prior to evaluation of the biopsy Exclusion Criteria: 1. Pregnant or lactating women 2. Ongoing oncological treatment for another cancer 3. Exclusively brain metastasis 4. Allergy to FDG

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm Disease Progression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic breast cancer Response monitoring

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aalborg University Hospital

    RECRUITING

    Aalborg, 9000, Denmark

  • Aarhus University Hospital

    RECRUITING

    Aarhus, 8200, Denmark

  • Esbjerg and Grindsted Hospital

    RECRUITING

    Esbjerg, 6700, Denmark

  • Herlev and Gentofte Hospital

    RECRUITING

    Herlev, 2730, Denmark

  • Hospital of Southern Jutland

    RECRUITING

    Sønderborg, 6400, Denmark

  • Humanitas Research Hospital

    NOT_YET_RECRUITING

    Milan, 20089, Italy

  • Irccs Azienda Ospedaliero - Universitario Di Bologna

    RECRUITING

    Bologna, 40138, Italy

  • Klinikum Der Technischen Universität München

    NOT_YET_RECRUITING

    München, 81675, Germany

  • Lille Baelt Hospital

    RECRUITING

    Vejle, 7100, Denmark

  • Odense University Hospital

    RECRUITING

    Odense, 5000, Denmark

  • Rigshospitalet

    RECRUITING

    Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.